Amneal Pharmaceuticals, Inc. Class A Aktie News

Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to support the pre-IND development of KFRX06, KeifeRx's preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2...

BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics Licensing Applications (BLAs) for Boncresa™ (denosumab-mobz), a biosimilar referencin...

Today's article presents why Amneal should get my prior buy rating from September reaffirmed. Although some technical signals support a hold rather than bullishness, fundamental analysis shows several upside drivers, including a robust and growing drug portfolio. Despite negative equity, the company also raised its operating cash flow guidance for FY25.

BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departmen...

BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson's Study Group (PSG) Annual Meeting.

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's albuterol sulfate inhalation aerosol (90 mcg per actuation).

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences: